Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
A Phase 2 Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada, G1R 2J6
- Chuq Pavillon Hotel-Dieu
-
-
Alberta
-
Calgary,, Alberta, Canada, T2N 4N2
- Tom Baker Cancer Center
-
Edmonton, Alberta, Canada, T6G1Z2
- Cross Cancer Institute
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3V 1N1
- Cal Andreou, MD
-
Victoria, British Columbia, Canada
- Can-Med Medical Research Inc
-
-
Nova Scotia
-
Kentville, Nova Scotia, Canada, B4N4K9
- Bruce W. Palmer Urology Inc.
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 4S5
- The Male Health Centres
-
Burlington, Ontario, Canada, L7N 3V2
- Burlington Professional Centre
-
Hamilton,, Ontario, Canada, L8N 1T8
- Hamilton & District Urology Association
-
London, Ontario, Canada, N6A 4G5
- London Health Sciences Centre
-
Markham, Ontario, Canada, L6B1A1
- Quest Clinical Trials
-
North Bay, Ontario, Canada, P1B4Z2
- Guardian Medical Arts Bldg.
-
North York, Ontario, Canada, M6A 3B5
- Jack Barkin, MD
-
Oakville, Ontario, Canada, L6H 3P1
- The Male Health Centres
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook &Women's College Health Sciens Center
-
-
Quebec
-
Montreal, Quebec, Canada, H2L 4M1
- Hôpital Notre-Dame
-
-
-
-
Alabama
-
Homewood,, Alabama, United States, 35205
- Urology Centers of Alabama
-
-
Alaska
-
Anchorage, Alaska, United States, 99508
- Alaska Clinical Research Center, LLC
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Arkansas Urologial Associates, PA
-
-
California
-
La Mesa, California, United States, 91942
- San Diego Urology Center
-
Torrance, California, United States, 90505
- Western Clinical Research Inc
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University Medical Center
-
-
Florida
-
Fort Myers, Florida, United States, 33916
- Clinical Physiology Associates
-
Tallahassee, Florida, United States, 32308
- Southeastern Urological Center, PA
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Maryland
-
Baltimore, Maryland, United States, 21231-1000
- Johns Hopkins Oncology Center
-
-
Nevada
-
Las Vegas, Nevada, United States, 89109
- Sheldon Freedman MD
-
Reno, Nevada, United States, 89511
- Nevada Urology Associates
-
Reno, Nevada, United States, 89502
- VA Medical Center(111)
-
-
North Carolina
-
Charlotte,, North Carolina, United States, 28204
- Carolinas Medical Centre
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
-
Oklahoma
-
Tulsa,, Oklahoma, United States, 74104-5433
- Urologic Specialists of Oklahoma, Inc.
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- Oregon Urology Specialists
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States, 17604-3200
- Urological Assoc. of Lancaster
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh
-
West Reading, Pennsylvania, United States, 19611
- Center for Urologic Care
-
West Reading,, Pennsylvania, United States, 19611
- Center for Urologic Care
-
-
Texas
-
Dallas, Texas, United States, 75230
- nTouch Research Corporation
-
-
Utah
-
Salt Lake City, Utah, United States, 84124
- Salt Lake Research
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington Medical Center
-
Seattle,, Washington, United States, 98166-3059
- Jeffrey Frankel, M.D.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- prostate adenocarcinoma,
- radical prostatectomy,
- PSA between 0.4 and 5 ng/mL,
- PSADT < 1 year
Exclusion Criteria:
- previous hormonal therapy,
- salvage therapy to the pelvis within 3 months prior to randomization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Evaluate the safety and efficacy of 10mg atrasentan in hormone naive subjects, as measured by the rate of rise in PSA.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Darryl Sleep, M.D., Abbott
Study record dates
Study Major Dates
Study Start
Study Start
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- M01-366
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.